Becton, Dickinson and (NYSE:BDX) PT Lowered to $255.00

Becton, Dickinson and (NYSE:BDXGet Rating) had its target price cut by Piper Sandler from $265.00 to $255.00 in a research note released on Thursday, The Fly reports.

A number of other analysts also recently commented on BDX. SVB Leerink upped their price objective on Becton, Dickinson and from $270.00 to $275.00 and gave the stock a market perform rating in a report on Friday, February 4th. Wells Fargo & Company upped their price objective on Becton, Dickinson and from $275.00 to $285.00 and gave the stock an equal weight rating in a report on Friday, April 1st. StockNews.com assumed coverage on Becton, Dickinson and in a report on Thursday, March 31st. They set a buy rating for the company. Bank of America initiated coverage on Becton, Dickinson and in a report on Tuesday, March 1st. They set a neutral rating for the company. Finally, Argus raised their price objective on Becton, Dickinson and from $275.00 to $310.00 in a research report on Monday, February 28th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $275.63.

Shares of BDX stock opened at $255.58 on Thursday. The company has a quick ratio of 0.78, a current ratio of 1.23 and a debt-to-equity ratio of 0.68. The stock’s 50-day moving average price is $263.67 and its 200 day moving average price is $257.04. Becton, Dickinson and has a 52-week low of $235.13 and a 52-week high of $280.62. The stock has a market capitalization of $72.78 billion, a PE ratio of 44.92, a price-to-earnings-growth ratio of 3.08 and a beta of 0.64.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 EPS for the quarter, topping the consensus estimate of $2.99 by $0.19. Becton, Dickinson and had a return on equity of 14.87% and a net margin of 8.75%. The business had revenue of $5.01 billion for the quarter, compared to analyst estimates of $4.78 billion. During the same quarter in the previous year, the company earned $3.19 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts expect that Becton, Dickinson and will post 12.75 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be given a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.36%. Becton, Dickinson and’s payout ratio is 60.21%.

In other Becton, Dickinson and news, EVP Betty D. Larson sold 14,374 shares of the company’s stock in a transaction on Friday, February 25th. The stock was sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Claire Fraser sold 841 shares of the company’s stock in a transaction on Tuesday, February 8th. The shares were sold at an average price of $271.70, for a total value of $228,499.70. The disclosure for this sale can be found here. 0.50% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of BDX. Norges Bank acquired a new position in Becton, Dickinson and in the fourth quarter worth about $663,055,000. Diamond Hill Capital Management Inc. bought a new stake in shares of Becton, Dickinson and during the fourth quarter valued at approximately $395,149,000. Morgan Stanley boosted its stake in Becton, Dickinson and by 16.9% in the second quarter. Morgan Stanley now owns 9,175,000 shares of the medical instruments supplier’s stock valued at $2,231,268,000 after acquiring an additional 1,323,224 shares during the last quarter. Invesco Ltd. boosted its stake in Becton, Dickinson and by 62.3% in the third quarter. Invesco Ltd. now owns 2,570,401 shares of the medical instruments supplier’s stock valued at $631,857,000 after acquiring an additional 986,940 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in Becton, Dickinson and by 6.1% in the third quarter. Wellington Management Group LLP now owns 14,489,749 shares of the medical instruments supplier’s stock valued at $3,561,871,000 after acquiring an additional 837,802 shares during the last quarter. 86.58% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

The Fly logo

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.